Clinical Trial Update: Bioavailability Study of Vemurafenib in Participants With BRAF^V600 Mutation-Positive Malignancies [Phase 1]

View source ↗

Summary

Phase 1 bioavailability study of vemurafenib in participants with BRAF V600 mutation-positive malignancies has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Malignant Melanoma

Drugs mentioned

• Vemurafenib (vemurafenib)

Snippet

Sponsor: Hoffmann-La Roche | Conditions: Malignant Melanoma, Cancer | Phase 1 | Status: COMPLETED